Liposomal Influenza Vaccine

Publisher Website
Google Scholar
Abstract
▴ This trivalent liposomal influenza vaccine consists of purified influenza haemagglutinin inserted into a membrane of phosphatidylcholine and phosphatidylethanolamine. It contains 15μg of haemagglutinin per viral strain per dose. ▴ The vaccine is immunogenic in the elderly, in younger adults and in children and adolescents with or without cystic fibrosis. ▴ Seroconversion rates were significantly higher with the liposomal vaccine than with a subunit vaccine for 3 of 3 and 2 of 3 strains in 2 published studies. Seroconversion occurred in a significantly greater number of participants receiving the liposomal vaccine than in those receiving a whole virus vaccine for all 3 strains in 1 study. ▴ Seroprotection rates were significantly better with the liposomal vaccine than with a subunit vaccine for 2 of 3 and 1 of 3 strains in 2 trials, and greater than with a whole virus vaccine for 2 of 3 strains in 1 trial. ▴ In a study in children with cystic fibrosis, a single dose of the liposomal vaccine was reported to have greater immunogenicity than 2 half doses (statistical analysis not performed). ▴ Local adverse reactions such as pain at the injection site, local induration, redness and swelling are transient and usually mild. ▴ Liposomal influenza vaccine did not induce a mean antiphospholipid antibody response in elderly volunteers.

This publication has 0 references indexed in Scilit: